for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

RedHill Biopharma Ltd

RDHL.OQ

Latest Trade

6.10USD

Change

0.00(0.00%)

Volume

108,794

Today's Range

6.05

 - 

6.49

52 Week Range

5.15

 - 

9.55

As of on the Tel Aviv Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
6.10
Open
6.49
Volume
108,794
3M AVG Volume
6.56
Today's High
6.49
Today's Low
6.05
52 Week High
9.55
52 Week Low
5.15
Shares Out (MIL)
352.70
Market Cap (MIL)
801.38
Forward P/E
-4.66
Dividend (Yield %)
--

Next Event

Redhill Biopharma Ltd Corporate Analyst Meeting

Latest Developments

More

Redhill Biopharma Announces FDA Approval Of Talicia® For Treatment Of H. Pylori In Adults

Redhill Biopharma Announces $36 Million Strategic Investment By Cosmo Pharmaceuticals And U.S. Rights To Approved Travelers' Diarrhea Drug AEMCOLO

Redhill Biopharma Announces Full Results From Positive MAP US Phase 3 Study

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About RedHill Biopharma Ltd

Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools. Its clinical-stage pipeline includes: TALICIA (RHB-105), an oral combination therapy for the treatment of Helicobacter pylori infection; RHB-104, an oral combination therapy for the treatment of Crohn's disease; BEKINDA (RHB-102), a once-daily oral pill formulation of ondansetron; RHB-106; YELIVA (ABC294640); MESUPRON, and RIZAPORT (RHB-103).

Industry

Biotechnology & Drugs

Contact Info

21 Ha'arba'a St.

+972.3.5413131

https://www.redhillbio.com/

Executive Leadership

Dror Ben-Asher

Chairman of the Board, Chief Executive Officer

Micha Ben Chorin

Chief Financial Officer

Gilead Raday

Chief Operating Officer

Reza Fathi

Senior Vice President - Research & Development

Adi Frish

Senior Vice President - Business Development and Licensing

Key Stats

Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-0.240

2017

-0.260

2018

-0.170

2019(E)

-0.139
Price To Earnings (TTM)
--
Price To Sales (TTM)
33.35
Price To Book (MRQ)
5.77
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-121.19
Return on Equity (TTM)
-88.06

Latest News

Latest News

U.S. FDA approves RedHill's bacterial infection treatment

RedHill Biopharma Ltd's said on Monday its three-drug combination therapy to treat Helicobacter pylori bacterial infections had been approved by the U.S. Food and Drug Administration, sending its shares up 25%.

U.S. FDA approves RedHill's H. pylori infection treatment

The U.S. Food and Drug Administration has approved RedHill Biopharma Ltd's drug to treat infections caused by bacteria known as Helicobacter pylori, the Israel-based company said on Monday.

RedHill Biopharma's antibiotic succeeds in late-stage study

Israel-based RedHill Biopharma Ltd said on Monday its combination antibiotic met the main goal of a late-stage study testing the drug in patients with a type of bacterial infection that affects the stomach and small intestine.

RedHill Biopharma's antibiotic succeeds in late-stage study

Israel-based RedHill Biopharma Ltd said on Monday its combination antibiotic met the main goal of a late-stage study testing the drug in patients with a type of bacterial infection that affects the stomach and small intestine.

RedHill BioPharma has positive results from Crohn's disease trial

Israel's RedHill Biopharma said on Monday it had positive safety and efficacy results from a late-stage clinical trial with its treatment for Crohn's disease called RHB-104.

BRIEF-Redhill Biopharma Posts Q1 Loss Of $0.05 Per Ordinary Share

* REDHILL BIOPHARMA REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Redhill Biopharma Says Last Patient Assessed For Main Goal In Late-Stage Crohn's Disease Trial

* REDHILL BIOPHARMA ANNOUNCES LAST PATIENT ASSESSED FOR PRIMARY ENDPOINT IN RHB-104 PHASE III STUDY FOR CROHN’S DISEASE

BRIEF-RedHill Biopharma Reports Enrollment of 300th Patient in Confirmatory Phase III Study With Talicia

* REDHILL BIOPHARMA ANNOUNCES ENROLLMENT OF 300TH PATIENT IN CONFIRMATORY PHASE III STUDY WITH TALICIA® FOR H. PYLORI INFECTION

BRIEF-Redhill Biopharma Plans To Meet With FDA In Q2 Of 2018 To Discuss Design For One, Two Pivotal Phase III Studies With Bekinda 12 Mg

* PLANS TO MEET WITH FDA IN Q2 OF 2018 TO DISCUSS DESIGN FOR ONE OR TWO PIVOTAL PHASE III STUDIES WITH BEKINDA 12 MG FOR IBS-D Source text for Eikon: Further company coverage:

BRIEF-Redhill Biopharma Announces Two Oral Presentations On Bekinda® 24 Mg For Acute Gastroenteritis

* REDHILL BIOPHARMA ANNOUNCES TWO ORAL PRESENTATIONS ON BEKINDA® 24 MG FOR ACUTE GASTROENTERITIS AT THE SAEM 2018 ANNUAL MEETING

BRIEF-Redhill Biopharma Q4 Basic Loss Per Ordinary Share $0.05

* CASH BALANCE AS OF DECEMBER 31, 2017 WAS $46.2 MILLION, A DECREASE OF $20 MILLION, COMPARED TO $66.2 MILLION AS OF DECEMBER 31, 2016 Source text for Eikon: Further company coverage:

BRIEF-Redhill Biopharma Announces Final Results From Phase II Study With Bekinda For IBS-D

* REDHILL BIOPHARMA ANNOUNCES FINAL RESULTS FROM PHASE II STUDY WITH BEKINDA® FOR IBS-D

BRIEF-Redhill Biopharma Initiates Phase IIa Study With Abc294640(Yeliva) For Cholangiocarcinoma

* REDHILL BIOPHARMA ANNOUNCES INITIATION OF PHASE IIA STUDY WITH ABC294640 (YELIVA®) FOR CHOLANGIOCARCINOMA AT MAYO CLINIC AND MD ANDERSON Source text for Eikon: Further company coverage:

BRIEF-Redhill Biopharma provides 2017 year-end business update

* REDHILL BIOPHARMA LTD - COST REDUCTION PLAN IS IN PLACE TO GRADUALLY REDUCE AVERAGE QUARTERLY CASH BURN RATE IN 2018 TO APPROXIMATELY $8.5 MILLION

BRIEF-Redhill biopharma Q3 ‍loss per ordinary share US$0.09

* Redhill Biopharma reports 2017 third quarter financial results

BRIEF-Redhill Biopharma says last patient enrolled in Phase III study with RHB-104 for Crohn’s disease

* Redhill Biopharma announces last patient enrolled in the Phase III study with RHB-104 for Crohn's disease

BRIEF-RedHill Biopharma prices public offering of its American Depositary Shares

* RedHill Biopharma prices public offering of its American Depositary Shares

BRIEF-Redhill Biopharma announces proposed public offering of its American Depositary Shares

* Redhill Biopharma announces proposed public offering of its american depositary shares Source text for Eikon: Further company coverage:

BRIEF-IntelGenx and Redhill Biopharma resubmit Rizaport NDA to FDA

* Intelgenx and Redhill Biopharma resubmit Rizaport new drug application to the FDA

BRIEF-Redhill Biopharma and Intelgenx submit new drug application to FDA for Rizaport® for migraines

* Redhill Biopharma and Intelgenx submit new drug application to FDA for Rizaport® for migraines

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up